Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530129 | 0.87 | TP53 (0.53) | TP53TSHRALDH1A1GLAMAPK1 | |
| SCHEMBL6570853 | 0.85 | KMT2A (0.51) | TP53TSHRALDH1A1GLAMAPK1 | |
| SCHEMBL3486247 | 0.84 | TP53 (0.71) | TP53TSHRALDH1A1GLAKMT2A | |
| SCHEMBL4301694 | 0.84 | GAA (0.56) | TP53TSHRALDH1A1GLAMAPK1 | |
| SCHEMBL5482146 | 0.83 | KMT2A (0.67) | TP53TSHRALDH1A1GLAMAPK1 | |
| SCHEMBL16463067 | 0.83 | TP53 (0.52) | TP53TSHRALDH1A1GLAMAPK1 | |
| SCHEMBL18275347 | 0.82 | KMT2A (0.56) | TP53TSHRALDH1A1GLAMAPK1 | |
| SCHEMBL18275268 | 0.82 | KMT2A (0.63) | TP53TSHRALDH1A1GLAMAPK1 | |
| SCHEMBL2183787 | 0.81 | TP53 (1.00) | TP53TSHRALDH1A1GLAKMT2A | |
| SCHEMBL3454955 | 0.81 | TP53 (0.67) | TP53TSHRALDH1A1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0287421-B1 | PROCESS FOR THE CYCLIC PRODUCTION OF HYDROGEN PEROXIDE | ELF ATOCHEM S.A. (FR) | 1991-06-05 | — | — | EP | claimed |
| EP-2673048-B1 | TREATMENT OF BIPOLAR DISORDER | ISIS INNOVATION (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-8901158-B2 | Treatment of bipolar disorder | ISIS INNOVATION LTD. (GB) | 2014-12-02 | — | — | US | disclosed |
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCQ, PRKCZ, PRKCH | TP53 1287/4885TSHR 1805/4885ALDH1A1 3943/4885 |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | TP53 4346/4885TSHR 319/4885ALDH1A1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.